Company profile PCRX

Pacira BioSciences Inc
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine lipo...some injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Show More
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences healthcare to provide analysis

Correlation between past revenue and Pacira BioSciences healthcare search interest

There is not enough data for Pacira BioSciences healthcare to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences healthcare to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences pain management to provide analysis

Correlation between past revenue and Pacira BioSciences pain management search interest

There is not enough data for Pacira BioSciences pain management to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences pain management to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences regenerative health to provide analysis

Correlation between past revenue and Pacira BioSciences regenerative health search interest

There is not enough data for Pacira BioSciences regenerative health to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences regenerative health to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 15:35:48.

After 39 days of this quarter the interest is at 319.0. Based on that we can calculate that during remaining 52 days it will total up to 744.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019575
838
45.7% QoQ
819
-2.3% QoQ
725
-11.5% QoQ
2020 732
27.3% YoY 1.0% QoQ
509
-39.3% YoY -30.5% QoQ
813
-0.7% YoY 59.7% QoQ
848
17.0% YoY 4.3% QoQ
2021 778
6.3% YoY -8.3% QoQ
822
61.5% YoY 5.7% QoQ
775
-4.7% YoY -5.7% QoQ
637
-24.9% YoY -17.8% QoQ
2022 901
15.8% YoY 41.4% QoQ
871
6.0% YoY -3.3% QoQ
901
16.3% YoY 3.4% QoQ
915
43.6% YoY 1.6% QoQ
2023 893
-0.9% YoY -2.4% QoQ
835
-4.1% YoY -6.5% QoQ
839
-6.9% YoY 0.5% QoQ
904
-1.2% YoY 7.7% QoQ
2024 319
-64.3% YoY -64.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and EXPAREL search interestLast update: February 09 2024 15:35:48.
Correlation coefficient between keyword and revenue is 0.68
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 15:35:50.

The average 5 years interest of EXPAREL was 62.26 per week.
The last year interest of EXPAREL compared to the last 5 years has changed by 4.37%.
The interest for EXPAREL is relatively stable in the last 5 years.
The last year interest is comparable to 5 years ago. It has changed only by 2.61%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 15:35:59.

After 39 days of this quarter the interest is at 230.0. Based on that we can calculate that during remaining 52 days it will total up to 537.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019499
905
81.4% QoQ
832
-8.1% QoQ
718
-13.7% QoQ
2020 691
38.5% YoY -3.8% QoQ
597
-34.0% YoY -13.6% QoQ
670
-19.5% YoY 12.2% QoQ
610
-15.0% YoY -9.0% QoQ
2021 621
-10.1% YoY 1.8% QoQ
731
22.4% YoY 17.7% QoQ
697
4.0% YoY -4.7% QoQ
589
-3.4% YoY -15.5% QoQ
2022 681
9.7% YoY 15.6% QoQ
685
-6.3% YoY 0.6% QoQ
657
-5.7% YoY -4.1% QoQ
562
-4.6% YoY -14.5% QoQ
2023 785
15.3% YoY 39.7% QoQ
728
6.3% YoY -7.3% QoQ
560
-14.8% YoY -23.1% QoQ
696
23.8% YoY 24.3% QoQ
2024 230
-70.7% YoY -67.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ZILRETTA search interestLast update: February 09 2024 15:35:57.
Correlation coefficient between keyword and revenue is -0.03
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 15:36:00.

The average 5 years interest of ZILRETTA was 52.66 per week.
The last year interest of ZILRETTA compared to the last 5 years has changed by -4.14%.
The interest for ZILRETTA is seasonal.
The last year interest is quite lower compared to 5 years ago. It has decreased by -19.72%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for iovera system to provide analysis

Correlation between past revenue and iovera system search interest

There is not enough data for iovera system to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for iovera system to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences non-opioid to provide analysis

Correlation between past revenue and Pacira BioSciences non-opioid search interest

There is not enough data for Pacira BioSciences non-opioid to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences non-opioid to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences bupivacaine liposome to provide analysis

Correlation between past revenue and Pacira BioSciences bupivacaine liposome search interest

There is not enough data for Pacira BioSciences bupivacaine liposome to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences bupivacaine liposome to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences triamcinolone acetonide to provide analysis

Correlation between past revenue and Pacira BioSciences triamcinolone acetonide search interest

There is not enough data for Pacira BioSciences triamcinolone acetonide to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences triamcinolone acetonide to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pacira BioSciences multivesicular liposome to provide analysis

Correlation between past revenue and Pacira BioSciences multivesicular liposome search interest

There is not enough data for Pacira BioSciences multivesicular liposome to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pacira BioSciences multivesicular liposome to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PCRX
Earnings date: 2024-02-28 After close
Company name: Pacira BioSciences Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-13T10:58:00-04:00

PR Newswire
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates

2026-05-13T12:00:00Z

GlobeNewswire
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

2026-05-12T20:01:00Z

GlobeNewswire
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

2026-05-08T12:00:00Z

GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-05T20:20:00Z

GlobeNewswire
Pacira BioSciences Mails Letter to Stockholders

2026-05-01T17:18:47Z

Analyst Upgrades
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24

2026-05-01T11:22:14Z

Analyst Upgrades
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32

2026-04-30T20:01:00Z

GlobeNewswire
Pacira BioSciences Reports First Quarter 2026 Financial Results

2026-04-28T20:20:00Z

GlobeNewswire
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders

2026-04-27T12:00:00Z

GlobeNewswire
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

2026-04-16T12:00:00Z

GlobeNewswire
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

2026-04-13T12:00:00Z

GlobeNewswire
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

2026-04-08T12:00:00Z

GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

2026-03-30T12:00:00Z

GlobeNewswire
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting

2026-03-26T12:46:21Z

Analyst Upgrades
Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $25